MedTrace Logo

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

NCT04175925 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2022-05-31

No results posted yet for this study

Summary

A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.

Conditions

  • Healthy Participants

Interventions

DRUG

BMS-986322

Specified Dose on Specified Days

OTHER

BMS-986322 Placebo

Specified Dose on Specified Days

DRUG

famotidine

Specified Dose on Specified Days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2021-07-13
Completion
2021-07-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175925 on ClinicalTrials.gov